Unprecedented discoveries have led to the development of novel targeted therapies for hepatitis C virus (HCV). These treatments—direct-acting antivirals (DAAs)— provide an extraordinary rate of sustained virological response (undetectable HCV blood concentrations for 6 months), curing chronic disease in most patients. However, recent studies suggest a potentially aggressive and early form of recurrent hepatocellular carcinoma in patients successfully treated with DAAs. These studies have sparked controversy as they have exposed potentially unwanted and unexpected consequences of the new HCV treatments.

Additional Metadata
Persistent URL dx.doi.org/10.1016/S2468-1253(16)30204-7, hdl.handle.net/1765/98009
Journal The Lancet Gastroenterology and Hepatology
Debes, J.D, Janssen, H.L.A, & Boonstra, P.A. (2017). Hepatitis C treatment and liver cancer recurrence: cause for concern?. The Lancet Gastroenterology and Hepatology (Vol. 2, pp. 78–80). doi:10.1016/S2468-1253(16)30204-7